POLD1 and neoplasm: The group of better responder patients displayed a neoantigen load and mutations in POLE, POLD1, and MSH2. Based on the premise that DNA repair loss results in elevated anti-tumor immune response, improved clinical outcomes were observed in patients with DNA repair gene mutations.